Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disease that is characterized
by the loss of dopamine. Since dopamine has trouble entering the blood–brain barrier, the utilization
of dendrimers and other nanomaterials is considered for conjugating the neurotransmitter and other
PD drugs. Dendrimers are three-dimensional, hyper-branched structures that are categorized into
several generations. Alpha-synuclein (ASN) is the protein involved in regulating dopaminergic
functions and is the main aggregate found inside Lewy bodies. Different types of dendrimers have
shown efficacy in disrupting the formation of unstable beta structures of ASN and fibrillation. The
conjugation of PD drugs into nanomaterials has elicited a prolonged duration of action and sustained
release of the drugs inside the BBB. The objectives of this study are to review the applications of a
dendrimer-based drug delivery system in addressing the root cause of Parkinson’s disease and to
emphasize the delivery of anti-Parkinson’s drugs such as rotigotine, pramipexole and dopamine
using routes of administration other than oral and intravenous.